Carisma to present new data on CAR-M therapy for hepatocellular carcinoma

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for the treatment of hepatocellular carcinoma, developed in collaboration with Moderna (MRNA). The abstract presents the first pre-clinical data on the development candidate targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid cells in vivo using lipid nanoparticles to deliver mRNA encoding CARs. The data show that this in vivo CAR-M therapy has significant potential as a treatment for GPC3+ solid tumors, including HCC.